Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.

Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP.

Cancer. 2010 Apr 1;116(7):1751-6. doi: 10.1002/cncr.24902.


A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.

Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C.

Cancer. 2010 Jul 15;116(14):3463-8. doi: 10.1002/cncr.25191.


The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M.

Cancer J. 2005 May-Jun;11(3):209-16.


Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN.

Cancer. 2009 Jan 1;115(1):119-27. doi: 10.1002/cncr.23987.


Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G.

Ann Oncol. 2006 Dec;17(12):1835-41. Epub 2006 Sep 15.


Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.

Chang W, Lee SJ, Park S, Choi MK, Hong JY, Kim YS, Maeng CH, Jung HA, Kim S, Lee J.

Melanoma Res. 2013 Apr;23(2):147-51. doi: 10.1097/CMR.0b013e32835efd8d.


Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS.

Cancer. 2005 Jan 15;103(2):329-38.


Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.

Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.

Cancer. 2004 Aug 1;101(3):596-603.


Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.

Pflugfelder A, Eigentler TK, Keim U, Weide B, Leiter U, Ikenberg K, Berneburg M, Garbe C.

PLoS One. 2011 Feb 16;6(2):e16882. doi: 10.1371/journal.pone.0016882.


Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.

Di Lorenzo G, Montesarchio V, Autorino R, Bellelli T, Longo N, Imbimbo C, Morelli E, Giannarini G, Mirone V, De Placido S.

Cancer. 2009 Feb 1;115(3):517-23. doi: 10.1002/cncr.24055.


Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.

Nathan FE, Berd D, Sato T, Mastrangelo MJ.

Cancer. 2000 Jan 1;88(1):79-87.


Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.

Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P.

Am J Clin Oncol. 2009 Oct;32(5):509-14. doi: 10.1097/COC.0b013e3181942a1f.


A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8.


Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.

Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, CaratenĂ­ G, Gentile A, Comella G.

Breast Cancer Res Treat. 1998 May;49(1):13-26.


Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.

Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C.

Anticancer Drugs. 2002 Jun;13(5):497-503.


A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.

Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H.

Clin Cancer Res. 2009 Mar 15;15(6):2158-65. doi: 10.1158/1078-0432.CCR-08-0629. Epub 2009 Mar 10.


Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN.

Ann Oncol. 1999 Apr;10(4):403-11.


Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.

O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, Haddad J, Kong S, Williams A, Jacobson E.

J Clin Oncol. 2009 Nov 10;27(32):5452-8. doi: 10.1200/JCO.2008.17.1579. Epub 2009 Oct 13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk